Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Daiichi Sankyo’s short-lived interest in the U.S. pain management market has officially come to an end, as the company's new CEO continues shifting its focus to oncology and the industry reels from the nation’s opioid crisis.